GENFIT S.A Current Ratio 2019-2022 | GNFT

GENFIT S.A current ratio from 2019 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
GENFIT S.A Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $0.24B $0.04B 6.33
2021-12-31 $0.32B $0.07B 4.27
2021-06-30 $0.15B $0.04B 3.92
2020-12-31 $0.21B $0.04B 5.95
2020-06-30 $0.26B $0.05B 5.71
2019-12-31 $0.33B $0.05B 6.66
2019-06-30 $0.34B $0.05B 6.45
2018-12-31 $0.26B $0.05B 5.56
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.208B $0.101B
Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00